Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
作者信息
Santi Daniel V, Cabel Luc, Bidard François-Clément
机构信息
Prolynx, San Francisco, CA, USA.
Medical Oncology, Institut Curie, Paris, France.
出版信息
Ann Transl Med. 2021 Jul;9(14):1113. doi: 10.21037/atm-21-1103.
Abstract
摘要
相似文献
1
Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?赛托珠单抗-戈维汀是作为传统抗体药物偶联物（ADC）、SN-38的前药，还是两者兼具？
Ann Transl Med. 2021 Jul;9(14):1113. doi: 10.21037/atm-21-1103.
2
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?SN-38 的长效前药在 sacituzumab govitecan 耐药肿瘤中是否有效？
BioDrugs. 2024 Mar;38(2):171-176. doi: 10.1007/s40259-024-00643-8. Epub 2024 Jan 18.
3
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.使用 sacituzumab govitecan 治疗转移性三阴性乳腺癌。
Expert Rev Anticancer Ther. 2021 Dec;21(12):1303-1311. doi: 10.1080/14737140.2021.1993065. Epub 2021 Oct 22.
4
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.靶向 TROP-2 并包含 SN-38 的抗体药物偶联物：抗 TROP-2 sacituzumab govitecan 的案例研究。
MAbs. 2019 Aug/Sep;11(6):987-995. doi: 10.1080/19420862.2019.1632115. Epub 2019 Jul 18.
5
Sacituzumab govitecan: an antibody-drug conjugate.戈沙妥珠单抗：一种抗体药物偶联物。
Expert Opin Biol Ther. 2017 Aug;17(8):1027-1031. doi: 10.1080/14712598.2017.1331214. Epub 2017 May 22.
6
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.注射用戈沙妥珠单抗：一种用于治疗难治性、转移性三阴性乳腺癌的抗体药物偶联物。
Ann Pharmacother. 2021 Jul;55(7):921-931. doi: 10.1177/1060028020966548. Epub 2020 Oct 17.
7
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.注射用戈沙妥珠单抗治疗转移性三阴性乳腺癌的临床概述和潜在毒性的管理。
Oncologist. 2021 Oct;26(10):827-834. doi: 10.1002/onco.13878. Epub 2021 Jul 10.
8
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.注射用戈沙妥珠单抗，一种新型第三代抗体药物偶联物（ADC），用于癌症治疗。
Expert Opin Biol Ther. 2020 Aug;20(8):871-885. doi: 10.1080/14712598.2020.1757067. Epub 2020 May 12.
9
Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan.7-乙基-10-羟基喜树碱的抗体药物偶联物：Sacituzumab govitecan 和 labetuzumab govitecan。
Eur J Med Chem. 2019 Apr 1;167:583-593. doi: 10.1016/j.ejmech.2019.02.017. Epub 2019 Feb 7.
10
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Sacituzumab govitecan（IMMU-132），一种用于治疗多种上皮癌的抗 Trop-2-SN-38 抗体药物偶联物：安全性和药代动力学。
Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.
引用本文的文献
1
Past, present and future of drug conjugates for cancer therapy.用于癌症治疗的药物偶联物的过去、现在与未来。
Nat Cancer. 2025 Sep 11. doi: 10.1038/s43018-025-01042-w.
2
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data.TROP-2靶向抗体药物偶联物治疗既往接受过治疗的晚期非小细胞肺癌患者的疗效和安全性：一项对重建患者数据的系统评价和汇总分析
Cancers (Basel). 2025 May 23;17(11):1750. doi: 10.3390/cancers17111750.
3
Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials.抗体药物偶联物用于肺癌治疗的疗效和安全性：对随机和非随机临床试验的系统评价
Pharmaceutics. 2025 May 3;17(5):608. doi: 10.3390/pharmaceutics17050608.
4
Profiling and cheminformatics bioprospection of curcurbitacin I and momordin Ic from on α-amylase and α-glucosidase.葫芦素I和苦瓜素Ic对α-淀粉酶和α-葡萄糖苷酶的分析及化学信息学生物活性筛选
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2492706. doi: 10.1080/14756366.2025.2492706. Epub 2025 Apr 29.
5
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors.戈沙妥珠单抗在实体瘤中的作用机制及临床疗效
Clin Cancer Res. 2025 Apr 14;31(8):1390-1399. doi: 10.1158/1078-0432.CCR-24-1525.
6
QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.一种瞬时失活抗体药物偶联物的QSP建模突出了短抗体半衰期的益处。
J Pharmacokinet Pharmacodyn. 2024 Dec 17;52(1):7. doi: 10.1007/s10928-024-09956-1.
7
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?SN-38 的长效前药在 sacituzumab govitecan 耐药肿瘤中是否有效？
BioDrugs. 2024 Mar;38(2):171-176. doi: 10.1007/s40259-024-00643-8. Epub 2024 Jan 18.
8
Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking.治疗性寡核苷酸：改善内体运输的化学策略展望。
Cells. 2023 Sep 11;12(18):2253. doi: 10.3390/cells12182253.
9
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.实体瘤肿瘤学中的抗体药物偶联物：靶向有效载荷带来的疗效收获。
Pharmaceutics. 2023 Aug 19;15(8):2160. doi: 10.3390/pharmaceutics15082160.
10
New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads.新型拓扑异构酶 I 抑制剂作为抗体药物偶联物弹头。
Clin Cancer Res. 2023 Mar 14;29(6):991-993. doi: 10.1158/1078-0432.CCR-22-3640.
本文引用的文献
1
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan 治疗转移性三阴性乳腺癌。
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
2
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.注射用戈沙妥珠单抗，一种新型第三代抗体药物偶联物（ADC），用于癌症治疗。
Expert Opin Biol Ther. 2020 Aug;20(8):871-885. doi: 10.1080/14712598.2020.1757067. Epub 2020 May 12.
3
Targeting Topoisomerase I in the Era of Precision Medicine.靶向精准医学时代的拓扑异构酶 I。
Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. doi: 10.1158/1078-0432.CCR-19-1089. Epub 2019 Jun 21.
4
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan-hziy 治疗难治性转移性三阴性乳腺癌。
N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.
5
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.一项评估 PF-06664178（一种靶向 Trop-2/Aur0101 的抗体药物偶联物）用于晚期或转移性实体瘤患者的 1 期、剂量递增研究。
Invest New Drugs. 2018 Oct;36(5):836-847. doi: 10.1007/s10637-018-0560-6. Epub 2018 Jan 15.
6
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.以 Trop-2 为靶点的拓扑异构酶 I 抑制剂抗体药物偶联物（ADC）治疗小细胞肺癌（SCLC）：Sacituzumab Govitecan。
Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5.
7
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Sacituzumab govitecan（IMMU-132），一种用于治疗多种上皮癌的抗 Trop-2-SN-38 抗体药物偶联物：安全性和药代动力学。
Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.
8
Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.曲妥珠单抗摄取及其与HER2阳性乳腺癌脑转移动物模型疗效的关系。
Breast Cancer Res Treat. 2017 Aug;164(3):581-591. doi: 10.1007/s10549-017-4279-4. Epub 2017 May 10.
9
In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.内化抗体RS7与人乳腺癌的体外和体内反应性
Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s.
Zotero 插件